|
Biolight Biofusion M300 Syringe Pump
Syringe pumps sit inside medication and fluid delivery workflows where configuration and documentation matter as much as the device itself. The Biofusion M300 is presented for wards, intensive care, operating rooms and infusion departments, with final specifications confirmed by quotation.
Biolight positions the Biofusion M300 as a medical pump for controlled medication and fluid delivery. The stated use environments are hospital wards, intensive care units, operating rooms and infusion departments, where infusion equipment is part of routine clinical operations rather than a standalone purchase.
The supplied material does not list fixed technical parameters. Instead, it says available parameters, accessories, software functions and supplied components depend on the chosen configuration and destination market. That makes the quotation stage central to understanding what a buyer would actually receive.
Procurement teams should treat the model name as a starting point, not a complete specification. They need confirmation of compatible accessories or consumables, minimum order quantity, lead time, warranty, training, regulatory documentation and international delivery before comparing offers.
Because the product is intended for clinical settings, the validation burden extends beyond the pump itself. Facility standards and local regulatory availability are named as configuration factors, so documentation and market suitability should be checked alongside price and hardware scope.
Why it matters:
For buyers, the key question is not simply which syringe pump is listed, but which configuration, accessories and regulatory documents are confirmed for the intended ward, ICU, operating room or infusion department.
View Product →
|
ScientificChina — tracking China’s science, technology, and industrial systems through the lens of real-world products.
Follow ScientificChina for deeper insight into the infrastructure behind global innovation.
Visit ScientificChina.
ScientificChina is an independent commercial platform and is not affiliated with or endorsed by any Chinese government agency or public institution.
|
|